Pharmacogenomics of TNF inhibitors
Tumor necrosis factor alpha inhibitors (TNFi) are biologic drugs that target TNFα, a key pro-inflammatory cytokine, to suppress disease activity and alleviate symptoms of various autoimmune diseases, including inflammatory bowel disease. This review focuses on the five US FDA-approved TNFi including...
Saved in:
| Main Authors: | Zainab Jan, Farah El Assadi, Dinesh Velayutham, Borbala Mifsud, Puthen Veettil Jithesh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521794/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenomics and Pharmacometabolomics in Precision Tramadol Prescribing for Enhanced Pain Management: Evidence from QBB and EMR Data
by: Dhoha Dhieb, et al.
Published: (2025-06-01) -
Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study
by: Dinesh Velayutham, et al.
Published: (2025-01-01) -
Mental health and psychotropic medication trends during the COVID-19 pandemic in a middle eastern population: A systematic analysis of electronic medical records from Qatar
by: Kholoud Bastaki, et al.
Published: (2025-08-01) -
Pharmacogenomic of LH and its receptor: are we ready for clinical practice?
by: Alessandro Conforti, et al.
Published: (2025-02-01) -
The role of TNF-α inhibitor in glioma virotherapy: A mathematical model
by: Elzbieta Ratajczyk, et al.
Published: (2016-12-01)